Safety & Risk Management

Motives for the use of serotonergic psychedelics: A systematic review

This systematic review of 37 studies found that serotonergic psychedelics are most commonly used to expand self‑awareness or spirituality (reported in 78% of studies), with coping (67%) and enhancement (57%) also frequent, and no consistent links to drug type, study method, year or user population. The authors suggest harm‑reduction services should offer non‑pharmacological ways to fulfil expansion motives and that future research examine motives for specific SPs.

Authors

  • Basedow, L. A.
  • Kuitunen-Paul, S.

Published

Drug and Alcohol Review
meta Study

Abstract

IssuesSerotonergic psychedelics (SP) are psychoactive substances that produce unique sets of subjective effects, such as hallucinatory experiences. This systematic review is the first to summarise which motives for SP use have been assessed in medical, psychological, sociological and ethnological research across different types of SPs and across cultural backgrounds. Findings on use motives can be especially important in the context of harm reduction.ApproachWe searched academic databases (Medline, Web of Science and Embase) and included publications if they were peer‐reviewed and written in English, German, Spanish or Dutch. We analysed which type of motives were reported, comparing motives from quantitative and qualitative reports, and investigating associations between motives and year of publication, specific SPs and specific participant populations.Key FindingsOur search in November 2020 resulted in 30,257 unique articles of which 37 were included in the analysis. Across all studies, the most common motive for SP use was the desire to expand awareness (78% of included studies), followed by coping (67%) and enhancement (57%) motives. There were no statistically significant associations between reported motive and type of report (quantitative vs. qualitative), year of publication (range: 1967–2020), type of SP and participant population.

Implications

If SP‐related harms are to be reduced, harm‐reduction services could focus on providing non‐pharmacological ways of fulfilling an expansion motive. Additionally, future studies should aim to assess specific motives for specific SPs.

Conclusions

SPs are most commonly used to expand (self‐)knowledge, promote spiritual development or for curiosity, notably across different SP user populations including patients.

Available with Blossom Pro

Research Summary of 'Motives for the use of serotonergic psychedelics: A systematic review'

Introduction

Psychoactive substances are used for many different reasons, and research on substance-use motives has developed models to explain why people use particular drugs. Based on motivational work in alcohol and cannabis research, a five-factor model of substance-use motives is often employed: social, conformity, coping, enhancement and expansion. The expansion motive—reflecting a wish to gain self-knowledge or alter perception—was added to capture motives more typical of substances with psychedelic properties. This review by Basedow and colleagues set out to fill a gap: no prior synthesised review had characterised motives for use specifically across the class of serotonergic psychedelics (SPs), which include tryptamines (for example psilocybin, DMT), ergolines (for example LSD) and phenethylamines (for example mescaline). The study aimed to summarise which motives have been assessed in the literature, compare findings from quantitative versus qualitative studies, and explore whether reported motives vary by year of publication, specific SPs, or participant populations. The investigators anticipated that qualitative and quantitative approaches might yield different frequencies of reported motives.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Study Details

  • Study Type
    meta
  • Journal
  • Topic
  • APA Citation

    Basedow, L. A., & Kuitunen‐Paul, S. (2022). Motives for the use of serotonergic psychedelics: A systematic review. Drug and Alcohol Review, 41(6), 1391-1403. https://doi.org/10.1111/dar.13480

References (20)

Papers cited by this study that are also in Blossom

The neurobiology of psychedelic drugs: implications for the treatment of mood disorders

Vollenweider, F. X., Kometer, M. · Nature Reviews Neuroscience (2010)

Phenomenology, Structure, and Dynamic of Psychedelic States

Preller, K. H., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)

Chemistry and Structure-Activity Relationships of Psychedelics

Nichols, D. E. · Current Topics in Behavioral Neurosciences (2017)

78 cited
Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens

Rickli, A., Moning, O. D., Hoener, M. C. et al. · European Neuropsychopharmacology (2016)

The therapeutic potential of psychedelic drugs: past, present, and future

Carhart-Harris, R. L., Goodwin, G. M. · Neuropsychopharmacology (2017)

Adverse effects of psychedelics: From anecdotes and misinformation to systematic science

Neil, J. C., Nutt, D. J. · Journal of Psychopharmacology (2022)

Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice

Palhano-Fontes, F., Gorman, I., Nielson, E. M. et al. · Frontiers in Psychology (2021)

Dimethyltryptamine (DMT): Subjective effects and patterns of use among Australian recreational users

Cakic, V., Potkonyak, J., Marshall, A. · Drug and Alcohol Dependence (2010)

67 cited
Show all 20 references
Experiences of Encounters with Ayahuasca - “the Vine of the Soul”

Kjellgren, A., Eriksson, A., Norlander, T. · Journal of Psychoactive Drugs (2009)

Heaven and Hell-A Phenomenological Study of Recreational Use of 4-HO-MET in Sweden

Kjellgren, A., Soussan, C. · Journal of Psychoactive Drugs (2011)

52 cited
Microdosing psychedelics: Motivations, subjective effects and harm reduction

Lea, T., Amada, N., Jungaberle, H. et al. · International Journal of Drug Policy (2020)

95 cited
Narrative identity, rationality, and microdosing classic psychedelics

Webb, M., Copes, H., Hendricks, P. S. · International Journal of Drug Policy (2019)

Psychedelics, meditation, and self-consciousness

Milliere, R., Carhart-Harris, R. L., Roseman, L. et al. · Frontiers in Psychology (2018)

Spontaneous and deliberate creative cognition during and after psilocybin exposure

Mason, N. L., Kuypers, K. P. C., Reckweg, J. T. et al. · Translational Psychiatry (2021)

86 cited
Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts

Noorani, T., Garcia-Romeu, A., Swift, T. C. et al. · Journal of Psychopharmacology (2018)

Cessation and reduction in alcohol consumption and misuse after psychedelic use

Garcia-Romeu, A., Davis, A. K., Fire Erowid et al. · Journal of Psychopharmacology (2019)

211 cited

Cited By (2)

Papers in Blossom that reference this study

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.